Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharma (NQ: RETA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharma

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA)
From Glancy Prongay & Murray LLP
Via Business Wire
REATA ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Shareholder Action Notice: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – RETA
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Reata Deadline Alert
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
ALERT: Reata Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RETA
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors
From Law Offices of Howard G. Smith
Via Business Wire
RETA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Reata Pharmaceuticals, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Law Offices of Frank R. Cruz Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
56 Biggest Movers From Yesterday
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares jumped 84% to close at $4.95 on Thursday after the company signed an exclusive summary distribution agreement... 
Via Benzinga
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet
Toward the end of trading Thursday, the Dow traded up 0.17% to 35,814.21 while the NASDAQ fell 1.13% to 15,608.30. The S&P also fell, dropping 0.28% to 4,688.20. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Looking At Reata Pharmaceuticals's Recent Whale Trades
Someone with a lot of money to spend has taken a bearish stance on Reata Pharmaceuticals (NASDAQ:RETA). And retail traders should know. We noticed this today when the big position... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) shares increased by 88.08% to $5.61 during Thursday's regular session. As of 12:30 EST, Ensysce Biosciences's stock is... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 1%; Inspira Technologies Shares Spike Higher
Midway through trading Thursday, the Dow traded down 0.18% to 35,691.63 while the NASDAQ fell 0.72% to 15,672.75. The S&P also fell, dropping 0.37% to 4,683.86. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 92.9% to $5.19 after the company signed an exclusive summary distribution agreement with Innovimed Sp... 
Via Benzinga
Why Reata Pharmaceuticals Stock Got Absolutely Crushed on Thursday
The biopharmaceutical company got some potentially devastating news from regulators. 
Via The Motley Fool
Reata Pharmaceuticals Stock Nosedives On FDA Panel's Rejection Of Kidney Drug
The vote was unanimous. Advisors said the evidence doesn't support the drug's merits. 
Via Investor's Business Daily
Exposures Product Safety
What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals
Over the past 3 months, 5 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ: 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low
Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Are Reata Pharmaceuticals Shares Plunging Premarket?
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted that the agency should not approve Reata Pharmaceuticals Inc's (NASDAQ: RETA) bardoxolone... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.